In 2021, 18F-DCFPyL received FDA approval as a diagnostic PET radiotracer for PSMA-positive lesions in patients with PCa and suspected metastases who are candidates for definitive therapy or with BCR. This evidence concerns the gene BCR and posterior cortical atrophy.